Related Experiment Video
Updated: Aug 16, 2025
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.7K
Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials.
Jasmine F Ashhurst1, Sicong Tu1, Hannah C Timmins1
1Brain and Mind Centre, University of Sydney, Camperdown, Australia.
Expert Review of Neurotherapeutics
|December 21, 2022
Summary
Precision medicine offers tailored treatments for Amyotrophic Lateral Sclerosis (ALS) by considering disease heterogeneity. This approach aims to improve clinical trial outcomes for ALS patients through personalized therapeutic strategies.
Area of Science:
- Neurology
- Clinical Trials
- Genetics
Background:
- Amyotrophic Lateral Sclerosis (ALS) presents significant clinical trial challenges due to low prevalence, poor prognosis, and disease heterogeneity.
- Advancing understanding of ALS phenotype and progression mechanisms fuels the evolution of clinical trial concepts.
Approach:
- Precision medicine in ALS leverages clinical phenotype, biomarkers, and genotyping for tailored treatment strategies.
- This review examines clinical trial design improvements to better meet patient and investigator needs in ALS research.
Key Points:
- Precision therapy targets specific ALS patient subgroups for more focused treatment.
- Increased community awareness and funding accelerate ALS research and therapeutic development.
Conclusions:
- Personalized medicine approaches are crucial for advancing ALS treatment.
- Optimizing clinical trial design is essential for effective ALS therapeutic development.
Related Concept Videos
01:11Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
01:15Parkinson's Disease: Overview
650
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
650
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:28Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
01:24Parkinson's Disease: Treatment
338
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
338
01:26Alzheimer's Disease: Overview
608
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
608